null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Daclizumab ELISA Kit (GXEL00053)

SKU GXEL00053
Product Type ELISA Kit
Assay Type Quantitative
Detection Method Colorimetric
Sensitivity 0.156 μg/ml
Range 0.31-5 μg/mL
Size 96T
Synonyms BIIB019, DAC HYP, 152923-56-3
€880
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Daclizumab ELISA Kit

The Daclizumab ELISA Kit (SKU: GXEL00053) is a high-sensitivity quantitative ELISA assay developed for the quantitative measurement of Daclizumab in Plasma, Serum. The assay delivers a detection range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml and is read colorimetrically at 450 nm, making it well suited to quantitative research workflows.

Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T cell activation, regulatory T cell expansion and survival, and activation-induced T-cell apoptosis. Because CD25 blockade reduces IL-2 consumption by effector T cells, it increases IL-2 bioavailability allowing for greater interaction with the intermediate-affinity IL-2R, and therefore drives the expansion of CD56bright natural killer (NK) cells. Furthermore, there appears to be a direct correlation between CD56bright NK cell expansion and DAC HYP efficacy in reducing relapses and MRI evidence of disease activity in patients with RMS in phase II and phase III double-blind, placebo- and active comparator-controlled trials. Therapeutic efficacy was maintained during open-label extension studies. However, treatment was associated with an increased risk of rare adverse events, including cutaneous inflammation, autoimmune hepatitis, central nervous system Drug Reaction with Eosinophilia Systemic Symptoms (DRESS) syndrome, and autoimmune Glial Fibrillary Acidic Protein (GFAP) alpha immunoglobulin-associated encephalitis. As a result, DAC HYP was removed from clinical use in 2018. The lingering importance of DAC is that its use led to a deeper understanding of the underappreciated role of innate immunity in the potential treatment of autoimmune disease.

Supplied with pre-coated microplates and all core reagents, the Daclizumab ELISA Kit gives you a validated, ready-to-use solution for Daclizumab research. Get accurate and reliable results with the Daclizumab ELISA Kit from Assay Genie.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose